Artículos de revistas
National Recommendations Based On Scientific Evidence And Opinions Of Experts On The Use Of Methotrexate In Rheumatic Disorders, Especially In Rheumatoid Arthritis. Results Of The 3e Initiative From Brazil [recomendações Nacionais Baseadas Em Evidências Científicas E Opiniões Dos Especialistas Sobre O Uso Do Metotrexato Nas Doenças Reumáticas, Especialmente Na Artrite Reumatoide. Resultados Da Iniciativa 3e Do Brasil]
Registro en:
Revista Brasileira De Reumatologia. , v. 49, n. 4, p. 346 - 361, 2009.
4825004
10.1590/S0482-50042009000400003
2-s2.0-70449688246
Autor
Pereira I.A.
Cruz B.A.
Xavier R.M.
Pinheiro G.D.R.C.
Titton D.C.
Giorgi R.D.N.
Da Rocha F.A.C.
Laurindo I.M.M.
Bertolo M.B.
Dougados M.
Institución
Resumen
Objectives: The use of methotrexate (MTX) has been the basis for rheumatoid arthritis (RA) therapy, but there is no uniformity on the guidelines for its clinical use. The objective of this study was to develop recommendations based on scientific evidence and opinions of experts on the use of MTX, which will allow the improvement of our clinical practice. Methods: 3E (Evidence, Expertise, Exchange) Initiative in Rheumatology is a multinational group of rheumatologists from 17 countries, including Brazil. After a selection of 10 questions about the use of MTX, held by the Delphi method, a systematic literature review (SLR) was done (Medline, Pubmed, Embase, Cochrane, Abstracts EULAR 2005-2007 and ACR 2006-2007) by six international bibliographic reviewers chosen by the mentors of the 3E study. Two other different national questions from Brazil were also included, and the SLR was done by a national bibliographic reviewer.** The results of SLR were presented by 7 members of our Brazilian 3E scientific committee* at a meeting of 48 rheumatologists, which discussed RSL details, voted, and produced the national recommendations presented here. These recommendations were subsequently used in the creation of multinational recommendations. Results and conclusions: 21 recommendations concerning the 10 international and the 2 national questions were formulated, with an agreement level of 77% among the participants (63-100%). Oral MTX should be started at a minimum dose of 10 mg/wk and a maximum dose of 25 mg/wk. Elevation of AST/ALT above 3x the upper limit, for at least 3 times consecutively, justifies the temporary suspension of MTX, which can be restored after normalization of serum liver enzyme levels; MTX is safe for long term use. The use of alcohol (100 g/wk) should be avoided. Combinations of MTX with disease modifying antirheumatic drugs are recommended, although there is risk of greater toxicity. Folic acid should be associated with MTX in dose higher than 5 mg/wk. Total blood cell count, creatinine, AST/ALT, serology for hepatitis B and C virus, and chest X-ray should be ordered before initiating MTX. Inquire about contraception methods, comorbidities, use of illicit drugs, alcohol, and liver diseases and hepatotoxic drugs should be performed. The MTX can be maintained during elective surgeries; discontinuation of MTX for at least 3 months before planning of pregnancy is suggested, for both men and women Use of contraception method is justified with the use of MTX in reproductive age. MTX can be used to reduce the cumulative dose of corticosteroid in patients with giant cell arthritis, rheumatic polymyalgia (RPM), juvenile dermatomyositis, and in systemic lupus erythematosus (SLE) with cutaneous or joint involvement. 49 4 346 361 Combe, B., Landewe, R., Lukas, C., Bolosiu, H.D., Breedveld, F., Dougados, M., Emery, P., Yazici, H., EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) (2007) Annals of the Rheumatic Diseases, 66 (1), pp. 34-45. , DOI 10.1136/ard.2005.044354 Sidiropoulos, P.I., Hatemi, G., Song, I.-H., Avouac, J., Collantes, E., Hamuryudan, V., Herold, M., Dougados, M., Evidence-based recommendations for the management of ankylosing spondylitis: Systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists (2008) Rheumatology, 47 (3), pp. 355-361. , DOI 10.1093/rheumatology/kem348 Visser, K., Katchamart, W., Loza, E., Martinez-Lopez, J.A., Salliot, C., Trudeau, J., Multinational Evidence-Based Recommendations for the Use of Methotrexate in Rheumatic Disorders with a Focus on Rheumatoid Arthritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists in the 3E Initiative (2008) Ann Rheum Dis, , 25/11/ 10.1136/ard.2008.094474 Van Tulder, M., Furlan, A., Bombardier, C., Bouter, L., Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group (2003) Spine, 28 (12), pp. 1290-1299. , DOI 10.1097/00007632-200306150-00014 http://ww.cebm.net/index.aspx?o=1025, Acessado em Março/2008Furst, D.E., Koehnke, R., Burmeister, L.F., Kohler, J., Cargill, I., Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis (1989) Journal of Rheumatology, 16 (3), pp. 313-320 Schnabel, A., Reinhold-Keller, E., Willmann, V., Gross, W.L., Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis (1994) Rheumatology International, 14 (1), pp. 33-38. , DOI 10.1007/BF00302669 Verstappen, S.M., Jacobs, J.W., Van Der Veen, M.J., Heurkens, A.H., Schenk, Y., Ter Borg, E.J., Intensive Treatment with Methotrexate in Early Rheumatoid Arthritis: Aiming for Remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) (2007) Ann Rheum Dis, 66, pp. 1443-1449 Lambert, C.M., Sandhu, S., Lochhead, A., Hurst, N.P., McRorie, E., Dhillon, V., Dose Escalation of Parenteral Methotrexate in Active Rheumatoid Arthritis That Has Been Unresponsive to Conventional Doses of Methotrexate: A Randomized, Controlled Trial (2004) Arthritis and Rheumatism, 50 (2), pp. 364-371. , DOI 10.1002/art.20167 Braun, J., Kästner, P., Flaxenberg, P., Währisch, J., Hanke, P., Demary, W., Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients with Active Rheumatoid Arthritis (2008) Arthritis Rheum, 58, pp. 73-81 Visser, K., Van Der Heijde, D., Incidence of Liver Enzyme Elevations and Liver Biopsy Abnormalities during Methotrexate Treatment in Rheumatoid Arthritis: A Systematic Review of the Literature (2008) Arthritis Rheum, 58 (SUPPL.), pp. S557 Shergy, W.J., Polisson, R.P., Caldwell, D.S., Rice, J.R., Pisetsky, D.S., Allen, N.B., Methotrexate-associated Hepatotoxicity: Retrospective Analysis of 210 patients with Rheumatoid Arthritis (1988) Am J Med, 85, pp. 771-774 Katchamart, W., Ortiz, Z., Shea, B., Tugwell, P., Bombardier, C., Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis (an Update Systematic Review and Metaanalysis) (2008) Arthritis Rheum, 58 (SUPPL.), pp. S473 Ros, S., Juanola, X., Condom, E., Canas, C., Riera, J., Guardiola, J., Del Blanco, J., Roig-Escofet, D., Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy (2002) Scandinavian Journal of Rheumatology, 31 (6), pp. 330-336. , DOI 10.1080/030097402320817040 Tilling, L., Townsend, S., David, J., Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis (2006) Clinical Drug Investigation, 26 (2), pp. 55-62. , http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/26320017.1/ adis/cdi/2006/00000026/00000002/art00001/ 76D55D1347F5E42E1140136761EA8508B345C81D94.pdf?link=http://www.ingentaconnect. com/error/delivery&format=pdf, DOI 10.2165/00044011-200626020-00001 Espinoza, L.R., Zakraoui, L., Espinoza, C.G., Gutiérrez, F., Jara, L.J., Silveira, L.H., Psoriatic Arthritis: Clinical Response and Side Effects to Methotrexate Therapy (1992) J Rheumatol, 19, pp. 872-877 Choi, H.K., Hernan, M.A., Seeger, J.D., Robins, J.M., Wolfe, F., Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study (2002) Lancet, 359 (9313), pp. 1173-1177. , DOI 10.1016/S0140-6736(02)08213-2 Van Halm, V.P., Nurmohamed, M.T., Twisk, J.W., Dijkmans, B.A., Voskuyl, A.E., Disease Modifying Antirheumatic Drugs are Associated with a Reduced Risk for Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Case Control Study (2006) Arthritis Res Ther, 8, pp. R151 Wolfe, F., Michaud, K., Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients (2004) Arthritis and Rheumatism, 50 (6), pp. 1740-1751. , DOI 10.1002/art.20311 Mariette, X., Cazals-Hatem, D., Warszawki, J., Liote, F., Balandraud, N., Sibilia, J., Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France (2002) Blood, 99 (11), pp. 3909-3915. , DOI 10.1182/blood.V99.11.3909 Doran, M.F., Crowson, C.S., Pond, G.R., O'Fallon, W.M., Gabriel, S.E., Predictors of Infection in Rheumatoid Arthritis (2002) Arthritis Rheum, 46, pp. 2294-2300 Wolfe, F., Michaud, K., Chakravarty, E.F., Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders (2006) Rheumatology, 45 (11), pp. 1370-1375. , DOI 10.1093/rheumatology/kel328 Katchamart, W., Trudeau, J., Phumethum, V., Bombardier, C., The Efficacy and Toxicity of Methotrexate Combination versus Monotherapy in Rheumatoid Arthritis: A Metaanalysis (2008) Arthritis Rheum, 58 (SUPPL-ACR 2008) Capell, H.A., Madhok, R., Porter, D.R., Munro, R.A.L., McInnes, I.B., Hunter, J.A., Steven, M., Ford, I., Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: Results from the double-blind placebo-controlled MASCOT study (2007) Annals of the Rheumatic Diseases, 66 (2), pp. 235-241. , DOI 10.1136/ard.2006.057133 Kremer, J.M., Genovese, M.C., Cannon, G.W., Caldwell, J.R., Cush, J.J., De Furst, Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis Despite Stable Doses of Methotrexate. A Randomized, Double-Blind, Placebo-Controlled Trial (2002) Ann Intern Med, 137, pp. 726-733 Tugwell, P., Pincus, T., Yocum, D., Stein, M., Gluck, O., Kraag, G., Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis (1995) N Engl J Med, 333, pp. 137-141. , The Methotrexate-Cyclosporine Combination Study Group Van Ede, A.E., Laan, R.F., Rood, M.J., Huizinga, T.W., Van De Laar, M.A., Van Denderen, C.J., Effect of Folic or Folinic Acid Supplementation on the Toxicity and Efficacy of Methotrexate in Rheumatoid Arthritis: A Forty-Eight Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study (2001) Arthritis Rheum, 44, pp. 1515-1524 Morgan, S.L., Baggott, J.E., Vaughn, W.H., Young, P.K., Austin, J.V., Krumdieck, C.L., The Effect of Folic Acid Supplementation on the Toxicity of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis (1990) Arthritis Rheum, 33, pp. 9-18 Morgan, S.L., Baggott, J.E., Vaughn, W.H., Austin, J.S., Veitch, T.A., Lee, J.Y., Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis. A Double-Blind, Placebo-Controlled Trial (1994) Ann Intern Med, 121, pp. 833-841 Griffith, S.M., Fisher, J., Clarke, S., Montgomery, B., Jones, P.W., Saklatvala, J., Do Patients with Rheumatoid Arthritis Established on Methotrexate and Folic Acid 5mg Daily Need to Continue Folic Acid Supplements Long Term? (2000) Rheumatology, 39, pp. 1102-1109. , Oxford Buckley, L.M., Vacek, P.M., Cooper, S.M., Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis (1990) Journal of Rheumatology, 17 (9), pp. 1158-1161 Kremer, J.M., Alarcon, G.S., Lightfoot Jr., R.W., Willkens, R.F., Furst, D.E., Williams, H.J., Methotrexate for Rheumatoid Arthritis. Suggested Guidelines for Monitoring Liver Toxicity (1994) Arthritis Rheum, 37, pp. 316-328. , American College of Rheumatology Erickson, A.R., Reddy, V., Vogelgesang, S.A., West, S.G., Usefulness of the American College of Rheumatology Recommendations for Liver Biopsy in Methotrexate-Treated Rheumatoid Arthritis Patients (1995) Arthritis Rheum, 38, pp. 1115-1119 Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis (1996) Arthritis Rheum, 39, pp. 723-731. , American College of Rheumatology Ad Hoc Committee on Clinical Guidelines Bértolo, M.B., Brenol, C.V., Schainberg, C.G., Neubarth, F., Lima, F.A.C., Laurindo, I.M., Update on the Brazilian Consensus for the Diagnosis and Treatment of Rheumatoid Arthritis (2007) Rev Bras Reumatol, 47, pp. 151-159 The Effect of Age and Renal Function on the Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis (1995) J Rheumatol, 22, pp. 218-223. , Rheumatoid Arthritis Clinical Trial Archive Group Alarcon, G.S., Kremer, J.M., Macaluso, M., Weinblatt, M.E., Cannon, G.W., Palmer, W.R., St Clair, E.W., Axiotis, C.A., Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study (1997) Annals of Internal Medicine, 127 (5), pp. 356-364 Golden, M.R., Katz, R.S., Balk, R.A., Golden, H.E., The Relationship of Preexisting Lung Disease to the Development of Methotrexate Pneumonitis in Patients with Rheumatoid Arthritis (1995) J Rheumatol, 22, pp. 1043-1047 Beyeler, C., Jordi, B., Gerber, N.J., Hof, V.I., Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: A longitudinal study (1996) Rheumatology, 35 (5), pp. 446-452 Sany, J., Anaya, J.-M., Canovas, F., Combe, B., Jorgensen, C., Saker, S., Thaury -, M.N., Gavroy, J.-P., Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis (1993) Journal of Rheumatology, 20 (7), pp. 1129-1132 Grennan, D.M., Gray, J., Loudon, J., Fear, S., Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery (2001) Annals of the Rheumatic Diseases, 60 (3), pp. 214-217. , DOI 10.1136/ard.60.3.214 Carpenter, M.T., West, S.G., Vogelgesang, S.A., Jones, D.E.C., Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy (1996) Orthopedics, 19 (3), pp. 207-210 Murata, K., Yasuda, T., Ito, H., Yoshida, M., Shimizu, M., Nakamura, T., Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery (2006) Modern Rheumatology, 16 (1), pp. 14-19. , DOI 10.1007/s10165-005-0444-4 Chakravarty, E.F., Sanchez-yamamoto, D., Bush, T.M., The Use of Disease Modifying Antirheumatic Drugs in Women with Rheumatoid Arthritis of Childbearing Age: A Survey of Practice Patterns and Pregnancy Outcomes (2003) J Rheumatol, 30, pp. 241-246 Mahr, A.D., Jover, J.A., Spiera, R.F., Hernandez-Garcia, C., Fernandez-Gutierrez, B., Lavalley, M.P., Merkel, P.A., Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis (2007) Arthritis and Rheumatism, 56 (8), pp. 2789-2797. , DOI 10.1002/art.22754 Ferraccioli, G., Salaffi, F., De Vita, S., Casatta, L., Bartoli, E., Methotrexate in polymyalgia rheumatica: Preliminary results of an open, randomized study (1996) Journal of Rheumatology, 23 (4), pp. 624-628 Caporali, R., Cimmino, M.A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial (2004) Annals of Internal Medicine, 141 (7), pp. 493-500 Fortin, P.R., Abrahamowicz, M., Du Berger, R., Nayak, V., Neville, C., Liang, M.H., Study of Methotrexate in Lupus Erythematosus (SMILE): Significant Decreased Disease Activity and Steroid Sparing Effect in Patients without Damage (2001) Arthritis Rheum, 44 (SUPPL.), pp. S387 Carneiro, J.R.M., Sato, E.I., Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus (1999) Journal of Rheumatology, 26 (6), pp. 1275-1279 Ramanan, A.V., Campbell-Webster, N., Ota, S., Parker, S., Tran, D., Tyrrell, P.N., Cameron, B., Feldman, B.M., The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids (2005) Arthritis and Rheumatism, 52 (11), pp. 3570-3578. , DOI 10.1002/art.21378 Dawson, J.K., Graham, D.R., Desmond, J., Fewins, H.E., Lynch, M.P., Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: A prospective study incorporating HRCT scanning and pulmonary function tests (2002) Rheumatology, 41 (3), pp. 262-267 Alarcon, G.S., Kremer, J.M., Macaluso, M., Weinblatt, M.E., Cannon, G.W., Palmer, W.R., St Clair, E.W., Axiotis, C.A., Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study (1997) Annals of Internal Medicine, 127 (5), pp. 356-364 Bartram, S.A., Experience with Methotrexate-Associated Pneumonitis in Northeastern England (1998) Arthritis Rheum, 41, pp. 1327-1328 Ohosone, Y., Okano, Y., Kameda, H., Fujii, T., Hama, N., Hirakata, M., Mimori, T., Ikeda, Y., Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis (1997) Journal of Rheumatology, 24 (12), pp. 2299-2303 Hilliquin, P., Renoux, M., Perrot, S., Puechal, X., Menkes, C.J., Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis (1996) Rheumatology, 35 (5), pp. 441-445 Golden, M.R., Katz, R.S., Balk, R.A., Golden, H.E., The Relationship of Pre-Existing Lung Disease to the Development of Methotrexate Pneumonitis in Patients with Rheumatoid Arthritis (1995) J Rheumatol, 22, pp. 1043-1047 Carroll, G.J., Thomas, R., Phatouros, C.C., Atchison, M.H., Leslie, A.-L., Cook, N.J., D'Souza, I., Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate (1994) Journal of Rheumatology, 21 (1), pp. 51-54 Chalmers, A., Scheifele, D., Patterson, C., Williams, D., Weber, J., Shuckett, R., Teufel, A., Immunization of patients with rheumatoid arthritis against influenza: A study of vaccine safety and immunogenicity (1994) Journal of Rheumatology, 21 (7), pp. 1203-1206 Fomin, I., Caspi, D., Levy, V., Varsano, N., Shalev, Y., Paran, D., Levartovsky, D., Elkayam, O., Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNFAlpha blockers (2006) Annals of the Rheumatic Diseases, 65 (2), pp. 191-194. , DOI 10.1136/ard.2005.036434 Kapetanovic, M.C., Saxne, T., Nilsson, J.-A., Geborek, P., Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients (2007) Rheumatology, 46 (4), pp. 608-611. , DOI 10.1093/rheumatology/kel366 Oren, S., Mendelboim, M., Brawn, Y., Paran, D., Ablin, J., Litinsky, I., Vaccination against Influenza in RA Patients: The Effect of Rituximab in Humoral Response (2007) Ann Rheum Dis, 66 (SUPPL. II), p. 363 Elkayam, O., Paran, D., Caspi, D., Litinsky, I., Yaron, M., Charboneau, D., Immunogenicity and Safety of Pneumococcal Vaccination in Patients with RA or SLE (2002) Clin Infec Dis, 34, pp. 147-153 Kapetanovic, M.C., Saxne, T., Sjöholm, A., Truedsson, L., Jönsson, G., Geborek, P., Influence of Methotrexate, TNF Blockers and Prednisolone on Antibody Responses to Pneumococcal Polysaccharide Vaccine in Patients with RA (2006) Rheumatology, 45, pp. 106-111 Elkayam, O., Yaron, M., Caspi, D., Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis (2002) Annals of the Rheumatic Diseases, 61 (7), pp. 623-625. , DOI 10.1136/ard.61.7.623 Ravikumar, R., Owen, T., Barnard, J., Almudevar, A., Anolik, J., Looney, J., ACR Meeting, 2006, , Anti-TNF Therapy in RA Patients Alters Hepatitis B Vaccine Responses. Poster presented at the